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The majority of proteins are unable to translocate into 
the cell interior. Hence for peptide- and protein-based 
therapeutics a direct intracytoplasmic delivery with the 
aid of transducing agents is an attractive approach. We 
wanted to deliver to the cell interior a putatively cyto-
toxic protein VPg. Protein transduction was achieved 
in vitro with three different commercial products. How-
ever, in our hands, delivery of various control proteins 
without known deleterious effects, as well as of pro-
tein VPg, always induced cell death. Finally, we used a 
novel transducing peptide Wr-T, which was not toxic to 
cultured cells, even in a quite large range of concentra-
tions. Most importantly, control protein delivered to cells 
in culture did not display any toxicity while VPg protein 
exerted a strong cytotoxic effect. These data show that 
results obtained with cell-penetrating agents should be 
interpreted with caution.
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InTRoducTIon
Due to their size and net charge the majority of 
proteins are unable to translocate into the cell interior, 
which significantly hampers the development of pep-
tide and protein-based therapeutics. For this reason di-
rect intracytoplasmic delivery of proteins is an attrac-
tive approach. Intracytoplasmic delivery of proteins has 
been attempted by conjugating cargo proteins to protein 
transduction domains (PTD), such as the HIV TAT, 
herpes simplex virus VP22 protein and others (Dietz, 
2010). The mechanism of PTD membrane translocation 
has largely remained elusive, but recent studies suggest 
that the PTD translocation seems to be due to strong 
cell surface interactions, sometimes followed by internal-
ization of the proteins into cells by classical endocytosis 
(Lundberg et al., 2003). Another approach is based on 
delivering the protein in a mixture with cationic lipids or 
other compounds able to interact with cell membranes 
(Weill et al., 2008; Bildstein et al., 2011). This interaction 
is followed by the passage of the mixture through the 
plasma membrane. It is an appealing method, as the pro-
teins remain free in the mixture and conceivably can be 
more easily liberated in an active form in the cell interior 
than when covalently attached to the PTD. In addition, 
this method is technically extremely simple. 
To find out if one of the viral proteins we study, VPg 
protein, might exert a cytotoxic effect on human cancer 
cells, we first transfected the cells with a plasmid bearing 
the VPg gene. We were, however, unable to recover the 
transfected cells, as all were dying 24 h after transfec-
tion, whereas an empty plasmid did not affect the cells 
(unpublished results). Therefore, to obtain the proof-of-
concept data we wanted to deliver the VPg protein di-
rectly to cells in culture. We used three different delivery 
compounds that by themselves showed negligible toxic-
ity. However, in our hands, the use of these transducers 
for delivery of either VPg protein or various proteins not 
known for exerting deleterious effects always induced 
cell death. Finally, we used an experimental transducing 
peptide Wr-T, with which we have been able to show 
the cytotoxic effect of VPg protein in cultured neoplastic 
cells, with no cytotoxic activity of control proteins.
MaTeRIals and MeTHods
Cells, antibodies and chemicals. HeLa and B16 
cells were grown in the D-MEM medium supplemented 
with 2 mM L-glutamine, 1% penicilin/streptomycin and 
10% fetal bovine serum. H358 cells (kind gift of R. Meu-
wissen) were cultured in the RPMI 1640 medium supple-
mented with 2mM L-glutamine, 1% penicilin/streptomy-
cin and 10% fetal calf serum (FCS). All eukaryotic cell 
lines were maintained in a humid incubator at 37°C in 
5% CO2. Escherichia coli BL21(DE3), BL21(DE3) (Rosetta 
strain)  and BL21(DE3) codon plus RIL were purchased 
in Novagen (Fontenay-sous-Bois, France). Bovine se-
rum albumin (BSA) was purchased from Calbiochem-
Novabiochem Corporation (La Jolla, CA, USA). Anti-
VPg polyclonal rabbit Ab was prepared in the Elevage 
Scientifique de Dombe (France) and purified by affinity 
chromatography on VPg-conjugated Affigel (Bio-Rad, 
France). The polyclonal anti-GST Ab was purchased 
from Sigma-Aldrich (France) and the rabbit polyclonal 
anti-LC3 Ab was purchased from Ozyme (France). Rab-
bit polyclonal Cy3-conjugated donkey anti-rabbit anti-
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bodies were purchased from Jackson ImmunoResearch 
(USA). Goat anti-rabbit HRP-conjugated antibodies were 
obtained from Promega (France). LDH cytotoxicity kit 
was purchased from Clontech (France).
Protein transduction reagents. Pro-Ject Protein 
Transfection Reagent was from Thermo Fischer Scien-
tific (Illkirch, France), TransPass P Protein Transfection 
Reagent was purchased from New England BioLabs 
(Frankfurt, Germany) and PULSin™ was from Polyplus-
transfection (Illkirch, France). Wr-T peptide (sequence 
KETWWETWWTEWWTEWSQGPGrrrrrrrrrr, where r 
is the D-enantiomer of arginine) was synthesized at Sig-
ma Genosys Co. Ltd. (Sapporo, Japan) and at GenScript 
Inc. (Piscataway, NJ, USA) by standard Fmoc chemistry 
on an ABI 433A peptide synthesizer (Applied Biosys-
tems, Foster City, CA). Crude peptide was purified by 
reverse-phase liquid chromatography on a C18 prepara-
tory column (Varian, Palo Alto, CA) and analyzed by 
mass spectrometry. 
Proteins. GST was expressed in E. coli BL21(DE3) 
(Rosetta strain) from pGEX-4TI plasmid (GE Health-
care, Meylan, France). The bacterial culture was grown 
at 37°C in the presence of ampicillin until an OD600 
0.6-1.0 was obtained. Cells were induced with 0.5 mM 
IPTG and grown at 37°C for 3–6 h. Bacteria were 
harvested by centrifugation, frozen in liquid nitrogen, 
and stored at –80°C. All subsequent purification steps 
were carried out at 4°C. Bacterial pellet was resus-
pended in 20 ml suspension buffer (50 mM phosphate 
buffer, pH 7.0, containing 300 mM NaCl, 0.2 mg/ml 
DNAse, 0.5 mg/ml lysozyme, supplemented with the 
protease inhibitor cocktail (Roche) and 1 mM PMSF), 
incubated for 30 min, disrupted three times by sonica-
tion for 1 min, and centrifuged for 60 min at 19 000 
r.p.m. (Beckmann rotor JA-20, at 4°C). The superna-
tant was loaded onto a GST-Sepharose column previ-
ously equilibrated in buffer A (50 mM phosphate buf-
fer, pH 7.0, containing 300 mM NaCl). After washing 
with buffer A (50 column volumes), the protein was 
eluted with 20 column volumes of 50 mM phosphate 
buffer, pH 7.0, containing 300 mM NaCl and 10 mM 
glutathione, and collected in 1 ml fractions. The frac-
tions containing GST protein were concentrated using 
Amicon Ultra concentrators to about 10 mg/ml and 
applied onto a Superose 12 column equilibrated with 
buffer A. Purified protein was collected in fractions 
of 0.5 ml, analyzed by SDS/PAGE, concentrated to 
6–10 mg/ml as described above, aliquoted, frozen in 
liquid nitrogen and stored at –80°C. 
His-tagged eGFP was expressed in E. coli BL21(DE3) 
cells from pLX02® plasmid (protein’eXpert, Grenoble, 
France). The bacteria were grown up to OD600 0.6–0.8 
in the presence of ampicillin and induced with 0.5mM 
IPTG for 16 h at 20°C. Bacterial lysate was prepared as 
described above and supernatant was loaded onto His-
trap column (GE Healthcare) equilibrated with PBS buf-
fer, pH 7.4. After extensive washing with PBS contan-
ing 20 mM imidazole, eGFP protein was eluted with 250 
mM imidazole in PBS.
Viral VPg protein was expressed from pGEX-4TI 
plasmid as a GST fusion in E. coli BL21(DE3) codon 
plus RIL strain. Bacteria were grown at 30°C in the pres-
ence of 100 µg/ml of ampicillin and induced with 0.1 
mM IPTG at OD600 = 0.6. After 4 h expression, cells 
from 1L were harvested and suspended in 50 ml of 50 
mM phosphate buffer, pH 7.0, containing 300 mM NaCl 
and supplemented with the protease inhibitor coctail and 
PMSF. The bacteria were lysed by sonication on ice. The 
lysates were then centrifuged at 19000 rpm for 50 min at 
4°C and the supernatants were filtered through 0.2 µm 
filters (Millipore) before applying onto the Glutathione-
Sepharose 4B (GE Healthcare) column. Washed GST-
VPg attached to the beads was cleaved with TEV pro-
tease (expressed and purified in our laboratory accord-
ing to Lucast et al.., 2001) overnight at 4°C. Untagged 
protein was next purified on Heparin-Sepharose column 
(GE Healthcare), using NaCl gradient.
Immunofluorescence microscopy. Cells were 
left to adhere for at least 24-36 h on poly-D-lysine-
coated coverslips in 60 cm2 dishes. After transduction 
at 60–70% confluency, cells were fixed by immers-
ing the coverslips in 2% paraformaldehyde in PBS, 
at 37°C for 20 min. After washing in PBS (3 times) 
cells were permeabilized with 0.2% Triton in PBS at 
room temperature for 5 min and immediately washed 
with PBS, 3 times for 5–10 min. Cells were stained 
with 50 µl of rabbit anti-VPg antibody diluted 1:400, 
in the antibody buffer (PBS with 3% BSA, 0.05% 
Tween and 0.02% sodium azide) and incubated for 
1 h at 37°C. After incubation the cells were washed 
3 times in PBS for 10 min at room temperature and 
subsequently incubated with a Cy3-conjugated donkey 
anti-rabbit secondary antibody for 30 min at 37°C, at 
1:250 dilution. After 3 washes in PBS the cell nuclei 
were counterstained with Hoechst nuclear stain (0.1 
µg/ml). Finally, the coverslips were washed in PBS 
(3 times for 5 min) and mounted on the microscopic 
slides with cryoprotector (Glycerol 90%). Images were 
collected with a BX61 motorized research microscope 
(Olympus) and restored by Volocity software (Impro-
vision). In parallel, control IgG provided by Biolabs 
was transduced with the TransPass reagent and trans-
duced cells were analysed as above.
Western blotting. The presence of VPg and GST 
proteins and LC3 authophagy marker in transduced 
cells was revealed as follows. HeLa cells (2–4×106) 
untreated or treated with GST or VPg protein were 
harvested, washed with PBS and subsequently lysed in 
100 µl of lysis buffer (50 mM Tris, pH 7.4, contain-
ing 250 mM NaCl, 0.1% NP-40, 0.1 mM PMSF, apro-
tinin at 10 mg/ml, leupeptin at 10 mg/ml and 100 
mM NaF) for 30 min on ice. Cell lysates were cleared 
for 10 min at 13 000 r.p.m., and the total protein con-
centration was measured by the Bradford or BCA 
method. Equal amounts of total protein or protein 
from equal amount of cells were resolved by SDS/
PAGE and electrotransferred for 8 min onto the 
PVDF membrane using iBlotTm transfer device (Invi-
trogen). Western blot was performed with anti-VPg, 
anti-GST and anti-LC3 antibodies diuted at 1/1000. 
The anti-pan-actin antibodies in dilution 1:1000 were 
used to reveal loading controls. After incubation with 
primary antibodies the membrane was washed and in-
cubated for 1 h at room temperature with secondary 
HRP-conjugated anti-rabbit antibody diluted 1:5000. 
Finally, the membranes were revealed with ECL.
Protein transduction, cell proliferation and cell 
damage assay. For commercial transductants cells 
grown in the 24-well plates were transduced at conflu-
ency of 60–70% with 0.5 or 1 µg BSA, VPg or eGFP 
proteins in a mixture with TransPass, or Pro-Ject or 
Pulsin (according to the manufacturers’ instructions), 
for 2–4 h in the absence of fetal calf serum, which 
was added after 4 h for longer incubation times. After 
the indicated periods of incubation at 37°C cells were 
used for estimation of cell proliferation by MTT assay 
(Sigma), of cell damage with LDH assay (Clontech) 
and for protein localization by immunofluorescence 
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microscopy (IF). For MTT assay 2×104cells were seed-
ed in 0.1 ml of medium in 96-well culture plates and 
allowed to attach for 24 h. Cells were transduced with 
0.2 mg of BSA, VPg and GST proteins for 2 or 24 
h. The culture medium was then removed and 100 µl 
EMEM medium containing 0.5 mg/ml MTT (Sigma) 
was added to each well. The plates were incubated, 
developed and read according to manufacturer‘s in-
structions, in Synergy HTi plate reader (Biotek, Win-
ooski VT, USA). The number of viable cells was cal-
culated as described by Mosmann et al. (1983).  Assays 
were performed in triplicate. For LDH assay, super-
natants (medium) from the cells transduced in 24-well 
plates were transferred to the 96-well plates and ana-
lyzed with LDH cytotoxicity kit (Clontech), accord-
ing to the manufacturer›s instructions. The tests were 
performed 3 times in duplicate and the significance of 
the difference between control and treated cells was 
estimated by t-criterion of Student. P-value<0.05 was 
considered as statistically significant.
For transduction with Wr-T peptide, cells grown in 
the 24-well plates were transduced at confluency 30% 
with a mixture of Wr-T peptide, according to Kondo 
et al. (2004). Shortly, cargo protein at 5 or 10 µg (10 
or 20 µM) per well was incubated with the Wr-T pep-
tide at 0.2 mM/well at room temperature for 45 min 
and the mixture was applied to cells in medium with 
serum. After periods of incubation of up to 72 h, the 
cell supernatants (medium) were transferred to 96-well 
plates and analyzed with LDH cytotoxicity kit (Clon-
tech), according to the manufacturer›s instructions. 
The tests were performed 3 times in duplicate and 
the significance of the difference between control and 
treated cells was estimated by t-criterion of Student. 
P-value<0.05 was considered as statistically significant. 
At some time points, cells were collected and analyzed 
by immunofluorescence mi-
croscopy or by Western blot, 
as described above.
ResulTs and dIscussIon
Our initial search for agents 
capable of direct protein trans-
duction led to three such com-
pounds, Pro-Ject Protein Trans-
fection Reagent, TransPass P 
Protein Transfection Reagent 
and PULSin™, which, according 
to the manufacturers, are able to 
directly and very efficiently de-
liver active proteins/antibodies 
to a large plethora of primary 
and transformed cells. ProJect is 
a cationic lipid mixture, Transp-
Pass is a non-lipid reagent, while 
Pulsin is a cationic lipid.
In the course of our work 
with VPg protein obtained by 
expression in E. coli, we used 
three irrelevant control proteins: 
bovine serum albumin (BSA), 
glutathione-S-transferase (GST) 
and the enhanced Green Fluo-
rescent Protein (eGFP). Albu-
min (583 amino acid residues, 
MW 66.430) is known to exert 
a protective effect in numerous 
biological systems. Due to its 
antioxidant activity, it reduces 
cell damage and acts as a neu-
roprotective molecule, reducing 
both DNA damage and apop-
tosis rates (Schmalz et al., 2000; 
Baltanas et al., 2008). It was 
shown to exert a stabilizing ef-
fect counteracting chemical drug 
Figure 1. Transduction of VPg protein with TransPass. 
B16 cells were transfected with 1 µg of VPg protein mixed with 
0.5 µg TP and analyzed at 24, 48, 72 and 96 h post-transfection by 
staining with anti-VPg Ab (red) and Hoechst nuclear dye (blue). C- 
non transfected cells, IgG-cells transfected with 1 µg IgG labeled 
with fluorescent dye (DyLight 549).
Figure 2. cytotoxicity observed after 4 h transduction in serum-free medium. 
Indicated cell lines were transduced with transductant alone or mixed with BSA or VPg and 
analyzed by LDH cytotoxicity kit as described in Methods. TransPass (TP) upper row, ProJect 
(PJ) — second row, Pulsin — third row. Triton — 100% damage observed with 0.2% Triton. 
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hydrolysis (Kurono et al., 2006). The glutathione-S-trans-
ferases (GST’s) are a multi-gene family of enzymes, in-
volved in detoxification of a wide range of endogenous 
and xenobiotic compounds, by catalyzing the conjuga-
tion of these compounds with glutathione. We did not 
find any data suggesting direct GST cytotoxicity towards 
mammalian cells. On the contrary, the microsomal GST 
was shown to protect against toxicity induced by silica 
nanoparticles (Shi et al., 2012). GST is often used to 
create fusion proteins and the resulting GST tag con-
tains 220 amino acids (pGEX vectors, GE Healthcare). 
Green Fluorescent Protein is a naturally fluorescent pro-
tein from the photoorgans of a jellyfish, Aequorea victoria. 
Wild-type GFP has several undesirable properties includ-
ing cell cytotoxicity (Liu et al., 1999). The “enhanced” 
GFP (eGFP) is a GFP variant that has been constructed 
to improve detection of GFP in transfected mammalian 
cells (Cormack et al., 1996; Zhang et al., 1996). It has 
been recently shown that eGFP exhibits cell-protective 
properties modulating the cytotoxicity of platinum-based 
drugs (Ceckova et al., 2008). We produced the eGFP of 
252 amino acids (MW 28,545) containing an amino-ter-
minal Met-Ala-(His)6-Gly-(His)3-Gln-Leu tag. 
First, we verified that VPg protein could not penetrate 
cells alone, without transducing agents. The presence of 
VPg protein in the medium did not result in a visible 
change of cell status, nor was the protein observed in-
side the cells by immunofluorescence microscopy (not 
shown). Then, VPg delivery was attempted with Trans-
Pass (TP) reagent. For this, cells in culture were trans-
duced with control fluorescent IgG and in parallel with 
VPg protein (Fig. 1). Transduction of both IgG and VPg 
proteins could be clearly observed, although only trace 
amounts of VPg protein could be seen at 48 h and no 
protein was visible at longer time points. Indeed, the 
manufacturer advises transduction at 37°C for 4 h and 
usually no longer than 24 h in a medium without serum, 
and further incubation in the presence of serum. Next, 
we tried to establish non-toxic conditions for the use of 
TP. Already at 4 h application, the observed cytotoxic-
ity of 0.5 µl TP alone was 10–20%, while that of 1 µl 
TP alone was nearly 100%. This indicated a rather nar-
row range of usable TP concentrations. We did not see 
this effect either with Pulsin or with Pro-Ject, for which 
doubling of the amount used resulted in a two-fold in-
crease in cytotoxicity, to an acceptable level (results non 
shown). 
We used three different cell lines transduced under 
comparable conditions, with BSA as a control protein, 
measuring the cytotoxicity after 4 h of treatment with 
the transductant in a serum-free medium (Fig. 2), fol-
lowed by 8 or 24 h incubation in a medium containing 
serum (Fig. 3). We observed that commercial transduc-
tants used at low cell confluency induced immediate 
cell death. Following the manufacturers’ suggestions, 
the cell confluency was increased to about 70%, permit-
ting the following experiments. 
At 4 h transduction both pro-
teins induced a similar level of 
cell damage, close to that induced 
by transductant alone, with some 
modulations (Fig. 2). Use of 0.5 
µl TransPass alone or in the pres-
ence of the protein resulted in 
mitigated damage, usually between 
20 and 30%. The application of 
eGFP or VPg protein did not af-
fect HeLa cells, whereas it some-
what increased cell damage in B16 
and H358 cells (Fig. 2, first row). 
When Pro-Ject was used, the pres-
ence of any of two translocated 
proteins did not increase cell dam-
age significantly (Fig. 2, second 
row), while with Pulsin (Fig. 2, 
third row), the presence of either 
protein resulted in increased cyto-
toxicity, weak in HeLa, and much 
more pronounced in B16 and 
H358 cells, in particular for eGFP 
(about 2–3-fold). When after 4 h 
transduction the cells were cul-
tured for an additional 8 or 24 h 
in a medium containing 10% calf 
serum, the increase in the amount 
of transducer (and also, presum-
ably, in the amount of the trans-
duced proteins) resulted in an in-
crease in cell damage, which was 
quite similar for both BSA and 
Table 1. survival of Hela cells upon transduction with TransPass
Cell survival
TP 0.2 µl GST 2 µg VPg 2 µg at 2 h at 24 h
+ – – 63% 63%
+ + – 40% 30%
+ – + 34% 38%
HeLa cells (2×104) were applied to 96-well plate, after 24 h transduc-
tion with TP alone or with mixture of TP with VPg or GST for 2 or 24 
h and analyzed by MTT assay as described in Methods. Data represent 
mean value from assay performed in triplicate.
Figure 3. cytotoxicity observed after 12 h (upper panels) and 28 h (lower panels) trans-
duction. 
Cells were transduced using TP for 4 h in serum-free medium. Further incubation for 8 or 
24 h, respectively, was done in serum-containing medium. LDH cytotoxicity assay was used 
as described in Materials and Methods. White columns — control with TransPass only; light 
gray — TP+BSA (1 µg); dark gray — TP+VPg (0.5 µg); black — TP+VPg (1 µg); T — 100% 
damage observed with 0.2% Triton. 
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VPg proteins (Fig. 3). These data were confirmed when 
another control protein, GST, was included in the exper-
imental design. When cytotoxicity was measured with the 
MTT assay, both GST and VPg delivered with Trans-
Pass during 2 or 24 h transduction exerted a comparable 
cytotoxic effect, reaching 60 to 70% inhibition of cell 
proliferation, which with transducer alone was around 
30% (Table 1).
Looking for the mechanism of TransPass cytotoxicity 
we investigated whether the activation of autophagy oc-
curred during use of TP. A reliable method for monitor-
ing autophagy and autophagic cell death is through de-
tection of the LC3 protein, and, in particular, appearance 
of the LC3-II form, resulting from cleavage of the LC3-
I form (Kabeya et al., 2000). Upon serum starvation that 
induces autophagy, the ratio of LC3-II/LC3-I increased 
somewhat in comparison to that observed in cells grown 
in the presence of serum (Fig. 4A, first two lanes). Im-
portantly, cells treated with TransPass alone or with 
transducing complexes containing eGFP or VPg also up-
regulated significantly and comparably the level of LC3-
II (Fig. 4). This suggests that TransPass alone triggers 
autophagy, which appears to increase in the presence of 
both proteins, as in the latter cases the ratio of LC3-
II/LC3-I was higher (Fig. 4B). Of note, also the treat-
ment of Huh7.5 cells with lipofectamine 2000 alone with 
the design of using it for the delivery of siRNA resulted 
in the increase of LC3-II protein and autophagosomal 
puncta (Mo et al., 2012). It is relevant that autophagy is 
a lysosomal degradation pathway for cytoplasmic com-
ponents such as proteins and organelles, contributing to 
prevention of the cytotoxic deposition of proteins in the 
cytoplasm (Scarlatti et al., 2009). However, although the 
presence of autophagy in dying cells is well documented, 
the precise role of autophagy in cell death is still unclear 
in many circumstances and is the subject of some con-
troversy, it seems that there is a very complex relation 
between autophagy and cell death (Kroemer & Levine, 
2008). We did not pursue this subject any further.
Finally, we tested transductant JBS-Proteoducin, which 
is a mixture of different cell penetrating peptides and 
proteins optimized for the internalization of a large va-
riety of proteins into living cells. HeLa cells treated with 
JBS-Proteoducin alone according to the product proto-
col were in visible distress at 24 h and died at 48 h of 
application, preventing its further use. Moreover, compa-
rable results were obtained with eGFP and VPg proteins 
(not shown). 
We found no scientific publications on the use of 
TransPass for direct protein delivery, but several labo-
ratories have used Pro-Ject and Pulsin. For example, the 
delivery of Granzyme B and Granzyme K was achieved 
with Pro-Ject (Lu et al., 2006; Zhao et al., 2007). Gran-
zymes are serine proteases able to activate specific path-
ways inducing cell death (reviewed by Chowdhury and 
Lieberman, 2008), and upon delivery of both Granzymes 
for just 4 h, apoptosis of transduced cells was observed. 
In addition, cell death was not observed upon transduc-
tion of a control protein, which was an inactive form 
of Granzyme (ops. cit.). In a study of Ig secretion by 
human plasmocytes, one of the SNARE components, 
SNAP-23 introduced with Pro-ject strongly inhibited Ig 
secretion, while GST alone did not exert this effect (Re-
ales et al., 2005). Pulsin was developed for the intracy-
Figure 4. effect of cell transduction on the expression of an au-
tophagy marker, lc3. 
H358 cells in 10 cm dishes were transduced at 70% confluency 
with eGFP and VPg proteins (80 µg/well) using TransPass reagent, 
as described in Methods. After 24 and 48 h cells were collected, 
lysed in lysis buffer (50 mM Tris, pH 7.4, containing 250 mM NaCl, 
0.1% NP-40, 0.1 mM PMSF, aprotinin at 10 µg/ml, leupeptin at 
10 µg/ml and 100 mM NaF) for 30 min on ice and processed for 
Western blot with anti-LC-3 antibody. C — control cells, S — cells 
grown in serum-free medium for 48 h. 
Figure 5. cytotoxicity observed after delivery of proteins using 
Wr-T peptide. 
Upper part shows Western blot done on the transduced with GST 
or VPg with aid of the Wr-T peptide, revealed with anti-VPg and 
anti-GST antibodies, respectively. Lower part:  HeLa cells grown 
in 24-well plates to about 30% confluency were transduced with 
GST or VPg (5 or 10 µg/well, 10 or 20 µM) proteins in mixture with 
Wr-T (0.2 mM/well) as described in Materials and Methods. At indi-
cated time points cytotoxicity was assessed using LDH cytotoxicity 
assay. 
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toplasmic delivery of anionic protein, with specific ap-
plication to antibody (Ab) delivery (Dalkara et al., 2004). 
Delivery of anti-Met tyrosine kinase Ab using Pulsin in-
duced inhibition of cell invasion, whereas the delivery of 
IgG did not interfere with this process (Cassinelli et al., 
2006). In another study, Pulsin-delivered Abs were used 
to determine the intracellular localization of a C. pneumo-
niae protein. Two different antibodies were shown to be 
immunoreactive with their respective intracellular targets, 
suggesting that Pulsin liposome does not compromise 
cell integrity (Cortes et al., 2007). 
We are not sure why our results are in contradiction 
with those cited above. It is conceivable that cells re-
act to the amount of transduced protein and perhaps in 
our hands the amount of translocated foreign proteins 
quickly exceeded the threshold permitting cell survival. 
Of note, the recommended time of incubation for these 
transductants is usually rather short — from several to 24 
h, and protein entry with the aid of these transductants 
can be visualized very shortly after application, which 
suggests an extremely efficient but not long-lasting pro-
cess. Indeed, our IF analysis showed that there is no for-
eign protein in cells transduced for longer times (Fig. 1). 
The mechanisms by which this type of protein translo-
cation might disrupt cellular function are not clear, but 
apparently the cells that survived were those that were 
able to get rid of the foreign protein. The cellular dam-
age upon massive entry of a foreign protein, independ-
ent of its function, can stem from mechanisms described 
as “gumming up the works,” namely, binding to and 
inactivating components of the cellular quality-control 
system, such as proteasome or chaperone proteins (Sa-
lomons et al., 2009). In addition, cellular dysfunction can 
be related to crowding at the expense of normal com-
ponents (Meredith, 2005, and references therein). It has 
been shown, for example, that the presence of heterolo-
gous proteins during expression in yeast can activate the 
unfolded-protein response (UPR) (Valkonen et al., 2003), 
which can have detrimental effects on cell function and, 
in the longer term, may induce apoptosis. However, 
UPR is an endoplasmic reticulum-related stress, and in 
order to avoid its induction we decided not to use DNA 
transfection but rather direct protein delivery. It is more 
probable that direct entry of cytoplasmic protein triggers 
an autophagic response, which is a cytoplasmic phenom-
enon. Interestingly, there are no communications on use 
of these transductants after 2008.
In further experiments we used a novel experimen-
tal transducing peptide, Wr-T. This transductant has an 
enlarged hydrophobic pocket consisting of triple trypto-
phan-rich domains fused with nine D-enantiomer pol-
yarginines (r9) via a Gly-Pro-Gly spacer, which serves 
to augment delivery of a cargo peptide (Kondo et al., 
2004). The Wr-T peptide was successfully employed for 
delivery of tumor suppressor peptides which resulted in 
significant inhibition of tumor cell growth (Kondo et al., 
2004; 2008). Last but not least, it requires only simple 
mixing with cargo, is applied to cells in serum-containing 
media, and there is no limitation on the transduction pe-
riod. 
First, using HeLa cells, we defined conditions for 
Wr-T use for protein delivery and confirmed by West-
ern blot the presence of the transduced proteins inside 
treated cells (see upper part of Fig. 5). It appeared that, 
in contrast with what was observed for peptide delivery 
with Wr-T (Kondo et al., 2004; 2008), higher amounts of 
transducing peptide were needed (200 µM instead of 5 
µM) with proteins at 5–10 µg (approximately 10–20 µM). 
At all analyzed time points, cell damage observed for 
Wr-T alone was similar to that for an untreated culture, 
and at 48 h it was still below 20%, similarly as for un-
treated cells (Fig. 5). GST protein did not induce cyto-
toxicity. Cytotoxic effect of VPg protein was not visible 
before 24 h, and at 48 h it reached 75–85% of cytotox-
icity, measured by LDH release. It can be inferred from 
these results that Wr-T-transduced proteins remain for a 
longer time in the cells. This might imply that the intra-
cytoplasmic compartment taken up by Wr-T-transduced 
proteins differs from that used by proteins delivered 
with commercial transducers.
conclusIons
Transductants used in this study transported cargo 
very efficiently and our data do not question the efficacy 
of delivery. However, it is conceivable that this remarka-
ble efficacy of cargo delivery might have induced a non-
specific cellular reaction. Our results indicate clearly that 
great caution is needed in the interpretation of results 
based on the delivery of therapeutic agents to cells with 
the aid of commercial transducing vectors. In order to 
obtain reliable data for the design of cytotoxic therapies, 
not only should appropriate control proteins be used, 
but also the effects exerted by the transductants should 
be strictly controlled and, if possible, understood. 
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